Terminated PHASE3 NCT01013623

Stage IV Surgery Versus Best Medical Therapy

A Phase III, Randomized Trial of Surgical Resection With or Without BCG Versus Best Medical Therapy as Initial Treatment in Stage IV Melanoma

Sponsor: Melanoma Research Alliance

Conditions Stage IV Resectable Melanoma

Interventions Surgery Surgery plus 2 adjuvant doses of BCG best medical therapy

Updated 7 times since 2017 Last updated: Sep 24, 2012 Started: Nov 30, 2009 Primary completion: Sep 30, 2012 Completion: Sep 30, 2012

A PHASE3 clinical study on Stage IV Resectable Melanoma, this trial is terminated or withdrawn. The trial is conducted by Melanoma Research Alliance and has accumulated 7 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Apr 2022 [monthly]

Terminated PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE3

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Melanoma Research Alliance
Saint John's Cancer Institute

Data source: Saint John's Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Brisbane, Australia , Buffalo, United States , Chicago, United States , Columbus, United States , Dallas, United States , Groningen, Netherlands , Hershey, United States , Murray, United States , Naples, Italy , Philadelphia, United States and 8 more locations